An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.Daniel Yick Chin Heng, Lori Wood, Min‐Han Tan et al.|Journal of Clinical Oncology|2012Cited by 18
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).Daniel Yick Chin Heng, Toni K. Choueiri, Jae‐Lyun Lee et al.|Journal of Clinical Oncology|2012Cited by 8
A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.Daniel Yick Chin Heng, Lori Wood, Toni K. Choueiri et al.|Journal of Clinical Oncology|2012Cited by 6
Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.Ying Wang, Daniel Yick Chin Heng, Toni K. Choueiri et al.|Journal of Clinical Oncology|2012Cited by 1
First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).Daniel Yick Chin Heng, Toni K. Choueiri, Brian I. Rini et al.|Journal of Clinical Oncology|2013Cited by 1